Clinical trials: Extensive Stage Small Cell Lung Cancer
- Condition Extensive Stage Small Cell Lung Cancer
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Extensive Stage Small Cell Lung Cancer
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
The primary aim of this study is to evaluate the efficacy of tarlatamab as assessed by objective response rate (ORR) based on blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1…
- Trial name
- DeLLphi-307 (NCT06502977)
- Testing
- Tarlatamab
- Where
- 12 sites in China
- Volunteers
- 32 people
- Sponsor
- Amgen
Extensive-stage Small Cell Lung Cancer
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared…
- Trial name
- NCT04702880
- Testing
- BMS-986012, Carboplatin, Etoposide
- Where
- 39 sites in United States, Australia and 9 more
- Volunteers
- 135 people
- Sponsor
- Bristol-Myers Squibb
Extensive Stage Small Cell Lung Cancer
A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC
This is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of HLX10+ Chemotherapy vs placebo+Chemotherapy in Previously Untreated Patients with Extensive Stage Small Cell…
- Trial name
- NCT04063163
- Testing
- HLX10, carboplatin and etoposide
- Where
- 5 sites in Georgia, Poland and 3 more
- Volunteers
- 585 people
- Sponsor
- Shanghai Henlius Biotech
Extensive-stage Small Cell Lung Cancer
Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer
Study to determine the safety and tolerability profile of durvalumab with platinum (cisplatin or carboplatin) plus etoposide (EP) as first-line treatment in participants with extensive-stage small-cell lung cancer.
- Trial name
- LUMINANCE (NCT04774380)
- Testing
- Durvalumab, Cisplatin, Carboplatin
- Where
- 35 sites in Bulgaria, Canada and 4 more
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Solid Tumor, Extensive-stage Small Cell Lung Cancer
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
This first-in-human (FIH) trial aimed to establish a safe dose of BNT411 as a monotherapy and in combination with atezolizumab, carboplatin and etoposide.
- Trial name
- NCT04101357
- Testing
- BNT411, Atezolizumab, Carboplatin
- Where
- 12 sites in United States, Germany and 2 more
- Volunteers
- 54 people
- Sponsor
- BioNTech SE
Lung Cancer, Small Cell Lung Cancer
QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer
This trial is titled "A Phase 1b/2 trial of AMG 479 or AMG 102 with Platinum-Based Chemotherapy as First-Line Treatment for Extensive Stage Small-Cell Lung Cancer (SCLC)." Part 1, the phase 1b portion of this study, is a…
- Conditions
- Lung Cancer, Small Cell Lung Cancer, Solid Tumors, Extensive-stage Small Cell Lung Cancer
- Trial name
- SCLC (NCT00791154)
- Testing
- AMG 479, Etoposide, AMG 102
- Volunteers
- 213 people
- Sponsor
- NantCell, Inc.
Extensive-stage Small-cell Lung Cancer
Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients
A Randomized, double-blind, placebo-controlled, multi-center Phase 3 study evaluating efficacy, safety and pharmacokinetics of Trilaciclib In Extensive-Stage Small Cell Lung Cancer Patients Receiving Carboplatin combined with…
- Trial name
- NCT04902885
- Testing
- Trilaciclib, carboplatin, etoposide，or Topotecan
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
Study design This is a Phase II, open-label, multi-drug, multi-center, multi-arm, signal-searching study in patients with extensive-stage small-cell lung cancer (SCLC) who have refractory or resistant disease from prior…
- Trial name
- NCT02937818
- Testing
- Durvalumab and Tremelimumab, AZD1775 and carboplatin (CBPT), AZD6738 and olaparib
- Where
- 12 sites in Germany, Hungary and 3 more
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Extensive Stage Small Cell Lung Carcinoma
A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma
The purpose of this trial is to compare the progression free survival of LY2510924 + carboplatin + etoposide therapy versus carboplatin + etoposide therapy in participants with extensive-stage disease small cell lung cancer (SCLC)
- Trial name
- NCT01439568
- Testing
- LY2510924, Carboplatin, Etoposide
- Where
- 15 sites in United States
- Volunteers
- 90 people
- Sponsor
- Eli Lilly and Company
Extensive-Stage Small-Cell Lung Cancer
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer
The purpose of this study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib given in combination with carboplatin and etoposide as initial therapy for patients with…
- Trial name
- NCT01987232
- Testing
- Carfilzomib, Carboplatin, Etoposide
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 32 people
- Sponsor
- Amgen